X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/getting-patented-meds-on-nlem-list-an-uphill-battle-says-committee-member/articleshow/94213010.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.fiercepharma.com/pharma/abbvie-medicines-patent-pool-ink-license-deal-for-hep-c-drug-mavyret-for-nearly-100
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en-0.pdf
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-hepatitis-c-drug-in-india/articleshow/64825917.cms
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded
https://www.fiercepharma.com/marketing/opdivo-repatha-and-lynparza-likely-among-china-s-2018-blockbuster-nods-report
http://www.prnewswire.com/news-releases/mylan-signs-sub-license-agreement-with-the-medicines-patent-pool-to-increase-access-to-hepatitis-c-treatment-in-developing-countries-300368162.html
http://www.drug-dev.com/Main/Back-Issues/HCV-MARKET-Recent-Success-in-HCV-Treatment-Brings-1213.aspx
http://www.pharmatimes.com/news/new_hep_c_drugs_grow_in_low-middle_income_countries_1174918
http://www.fiercepharma.com/pharma-asia/japan-s-pmda-reviews-hep-b-risk-link-to-hep-c-therapies
http://www.reuters.com/article/us-eu-hepatitis-c-idUSKCN0XC1MB
http://www.fiercepharmaasia.com/story/bms-phiii-hep-c-combo-results-milestone-china-plans/2016-02-22
http://www.fool.com/investing/general/2016/02/20/is-this-the-company-gilead-sciences-should-fear-mo.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
http://www.fiercepharma.com/story/gilead-nabs-two-new-harvoni-approvals-hep-c-contest-heats/2016-02-17
http://www.prnewswire.com/news-releases/the-medicines-patent-pool-signs-first-sub-licences-for-hepatitis-c-medicine-daclatasvir-565880261.html
http://www.business-standard.com/article/companies/cipla-to-sell-hepatitis-c-drug-daclatasvir-116012000742_1.html
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/desi-generics-firms-pave-way-for-cheaper-hepatitis-c-drug/articleshow/50611230.cms
http://www.business-standard.com/article/companies/torrent-launches-world-s-second-biosimilar-of-generic-auto-immune-drug-116011100615_1.html
http://health.economictimes.indiatimes.com/news/pharma/first-of-a-kind-drug-approvals-continued-rise-in-2015/50453714
http://www.fiercepharma.com/story/australia-bets-1b-pricey-hep-c-drugs-broad-effort-eradicate-disease/2015-12-23
http://www.abc.net.au/news/2015-12-20/federal-government-spending-1billion-on-hepatitis-c-treatment/7043624
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/hetero-receives-drug-controller-approval-for-generic-daclatasvir/articleshow/50172434.cms
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-gets-dcgi-nod-to-sell-hepatitis-c-treatment-drug/articleshow/50172371.cms
http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/hepatitis-c-cure-may-cost-as-low-as-rs-67000/articleshow/49967791.cms
http://www.pharmatimes.com/Article/15-11-26/Hep_C_patients_to_get_NHS_access_to_three_new_therapies.aspx
http://www.fiercepharmaasia.com/story/bms-gets-leg-china-hep-c-race-phi-daklinza/2015-11-18
http://www.bloomberg.com/news/articles/2015-11-04/gilead-s-sovaldi-tied-to-slow-heartbeat-in-hepatitis-c-patients?
http://www.fiercepharmaasia.com/story/indian-drugmakers-take-page-hiv-playbook-hep-c-combo-pill/2015-10-09
http://www.europeanpharmaceuticalreview.com/35440/news/industry-news/fda-grants-priority-review-for-hcv-treatment-daklinza-sndas/?
http://www.pharmatimes.com/Article/15-10-06/BMS_gets_speedy_US_review_for_Daklinza_applications.aspx?
http://www.pharmatimes.com/Article/15-09-11/EU_OKs_shorter_ribavirin-free_Daklinza_regimen_for_HCV.aspx?
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+aprova+ampliacao+de+uso+para+o+medicamento+daklinza
http://www.pmlive.com/pharma_news/limited_access_to_new_hep_c_treatments_under_the_spotlight_788876
http://blogs.wsj.com/pharmalot/2015/05/08/who-adds-hepatitis-c-and-cancer-drugs-to-its-list-of-essential-medicines/
http://www.fiercepharma.com/story/caforio-takes-ceo-role-bms-faces-tough-year-promising-new-drugs/2015-05-06
http://www.fiercepharmaasia.com/story/pharma-c-suite-notable-quotable-remarks-asia-emerging-markets-q1-part-5/2015-05-05-0
http://www.pmlive.com/pharma_news/bms_opdivo_backed_as_melanoma_therapy_in_eu_721486
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002310.jsp&mid=WC0b01ac058004d5c1
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/04/news_detail_002313.jsp&mid=WC0b01ac058004d5c1
http://www.fiercepharma.com/story/abbvie-moves-closer-japans-crowded-hep-c-field-priority-review-nod/2015-04-16
http://www.fiercepharmaasia.com/story/japan-pharma-market-track-80-billion-mark-2020-obstacles-seen/2015-03-31
Market Place
Share 
